Login / Signup

Large-scale plasma proteomic analysis identifies proteins and pathways associated with dementia risk.

Keenan A WalkerJingsha ChenJingning ZhangMyriam FornageYunju YangLinda ZhouMorgan E GramsAdrienne TinNatalie DayaRon C HoogeveenAozhou WuKevin J SullivanPeter GanzScott L ZegerElias Freyr GudmundssonValur EmilssonLenore J LaunerLori L JenningsVilmundur G GudnasonNilanjan ChatterjeeRebecca F GottesmanThomas H MosleyEric BoerwinkleChristie M BallantyneJosef Coresh
Published in: Nature aging (2021)
The plasma proteomic changes that precede the onset of dementia could yield insights into disease biology and highlight new biomarkers and avenues for intervention. We quantified 4,877 plasma proteins in nondemented older adults in the Atherosclerosis Risk in Communities cohort and performed a proteome-wide association study of dementia risk over five years (n = 4,110; 428 incident cases). Thirty-eight proteins were associated with incident dementia after Bonferroni correction. Of these, 16 were also associated with late-life dementia risk when measured in plasma collected nearly 20 years earlier, during mid-life. Two-sample Mendelian randomization causally implicated two dementia-associated proteins (SVEP1 and angiostatin) in Alzheimer's disease. SVEP1, an immunologically relevant cellular adhesion protein, was found to be part of larger dementia-associated protein networks, and circulating levels were associated with atrophy in brain regions vulnerable to Alzheimer's pathology. Pathway analyses for the broader set of dementia-associated proteins implicated immune, lipid, metabolic signaling and hemostasis pathways in dementia pathogenesis.
Keyphrases
  • mild cognitive impairment
  • cognitive impairment
  • cognitive decline
  • cardiovascular disease
  • randomized controlled trial
  • type diabetes
  • small molecule
  • fatty acid
  • dna methylation
  • staphylococcus aureus
  • binding protein